Anti-ADAM8 mAb
ADAM8-positive cancers (e.g., Colorectal, Breast, Kidney)
Pre-clinicalActive
Key Facts
Indication
ADAM8-positive cancers (e.g., Colorectal, Breast, Kidney)
Phase
Pre-clinical
Status
Active
Company
About Adecto Pharmaceuticals
Adecto Pharmaceuticals is a private, pre-clinical stage biotherapeutic company targeting ADAM8-positive cancers, including colorectal, breast, and kidney cancers, with a novel monoclonal antibody. Its technology is designed to overcome limitations of current immunotherapies by reprogramming both lymphoid and myeloid immune cells, not just T-cells. Founded by seasoned researchers, the company is led by CEO & CSO Dr. Nora Mineva and is focused on advancing its lead candidate through preclinical development. Adecto is currently pre-revenue and is engaged in fundraising and corporate development activities.
View full company profile